Effects of XXXX on lymphocyte subsets.

@entity1 @entity26344 @entity404 @entity1075 @entity2905 @entity9104 @entity405 @entity281 @entity15626 @entity15 @entity293
OBJECTIVE: To evaluate changes in absolute lymphocyte counts, lymphocyte subsets, and @entity281 in @entity1 treated with @entity15626 ( @entity9104 ) in comparison to the baseline pre- @entity9104 levels. METHODS: A retrospective chart review was conducted of 23 @entity15 @entity1 treated with @entity9104 . Absolute lymphocyte counts and lymphocyte subsets were obtained at baseline and after at least 3 months of @entity9104 treatment. Data on @entity281 requiring medical attention were also collected. RESULTS: A total of 23 @entity1 were included in this analysis, 11 male (48%), 12 female (52%), with a mean age of 44.5  14.1 years, disease duration of 13.7  8.9 years, and EDSS of 3.5  1.7. The time between baseline and treatment lymphocyte counts was 3.9  1.2 months. Significant reductions in absolute lymphocyte counts by 35% (p<0.0001), CD3(+) by 34% (p<0.0001), @entity404 (+) by 34% (p<0.0001), @entity405 (+) by 40% (p<0.0001), and @entity1075 (+) counts by 48% (p=0.0098) were found. Grade 2 @entity2905 occurred in 24% of @entity1 and grade 3 @entity2905 occurred in 1 @entity1 . @entity281 occurred in 26% of @entity1 , mainly as @entity293 (22%) and one fatal case of @entity26344 in a @entity1 with grade 3 @entity2905 , who had been on @entity9104 for 5 months. A detailed summary of this fatal case is provided. CONCLUSION: Lymphocyte subsets may help to provide better understanding of immunologic and safety impact of @entity9104 .
